Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ: REGN · Real-Time Price · USD
793.53
-9.64 (-1.20%)
Feb 17, 2026, 4:00 PM EST - Market closed
Regeneron Pharmaceuticals Revenue
In the year 2025, Regeneron Pharmaceuticals had annual revenue of $14.34B with 0.99% growth. Regeneron Pharmaceuticals had revenue of $3.88B in the quarter ending December 31, 2025, with 2.51% growth.
Revenue (ttm)
$14.34B
Revenue Growth
+0.99%
P/S Ratio
5.79
Revenue / Employee
$930,753
Employees
15,410
Market Cap
81.43B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 14.34B | 140.90M | 0.99% |
| Dec 31, 2024 | 14.20B | 1.08B | 8.27% |
| Dec 31, 2023 | 13.12B | 944.30M | 7.76% |
| Dec 31, 2022 | 12.17B | -3.90B | -24.26% |
| Dec 31, 2021 | 16.07B | 7.57B | 89.14% |
| Dec 31, 2020 | 8.50B | 1.94B | 29.58% |
| Dec 31, 2019 | 6.56B | 1.41B | 27.44% |
| Dec 31, 2018 | 5.15B | -726.60M | -12.37% |
| Dec 31, 2017 | 5.87B | 1.01B | 20.82% |
| Dec 31, 2016 | 4.86B | 756.67M | 18.44% |
| Dec 31, 2015 | 4.10B | 1.28B | 45.55% |
| Dec 31, 2014 | 2.82B | 714.81M | 33.96% |
| Dec 31, 2013 | 2.10B | 726.27M | 52.69% |
| Dec 31, 2012 | 1.38B | 932.65M | 209.20% |
| Dec 31, 2011 | 445.82M | -13.25M | -2.89% |
| Dec 31, 2010 | 459.07M | 79.81M | 21.04% |
| Dec 31, 2009 | 379.27M | 140.81M | 59.05% |
| Dec 31, 2008 | 238.46M | 113.43M | 90.73% |
| Dec 31, 2007 | 125.02M | 61.58M | 97.05% |
| Dec 31, 2006 | 63.45M | -2.75M | -4.15% |
| Dec 31, 2005 | 66.19M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Vertex Pharmaceuticals | 12.00B |
| Incyte | 5.14B |
| BeOne Medicines AG | 4.97B |
| Genmab | 3.85B |
| Alnylam Pharmaceuticals | 3.71B |
| BioNTech SE | 3.70B |
| argenx SE | 3.68B |
| Royalty Pharma | 2.38B |
REGN News
- 1 day ago - Ocular Therapeutix's eye drug superior to Regeneron's Eylea in late-stage trial - Reuters
- 5 days ago - Baird Chautauqua International Growth Fund: Q4 2025 Winners, Laggards, Buys & Sells - Seeking Alpha
- 6 days ago - Regeneron Announces Investor Conference Presentations - GlobeNewsWire
- 8 days ago - Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy - GlobeNewsWire
- 15 days ago - These Analysts Revise Their Forecasts On Regeneron Pharmaceuticals After Q4 Results - Benzinga
- 16 days ago - EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases - GlobeNewsWire
- 17 days ago - Regeneron: Expect Double-Digit Growth In 2026 - Seeking Alpha
- 18 days ago - Regeneron Pharmaceuticals, Inc. (REGN) Q4 2025 Earnings Call Transcript - Seeking Alpha